StockData
Alto Neuroscience, Inc. logo

Alto Neuroscience, Inc. (ANRO) stock

ANRONYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 4/30
$29.54−1.08 (-3.53%)

Close on Nov 13, 2026Market cap $1.16BP/E –Yield –

Alto Neuroscience r&d expenses

Research and development expenses are spending on new products and technology.

Alto Neuroscience's R&D Expenses for the twelve months ending Sep 30, 2026 was $72.56M, up 63.3% year over year. For fiscal 2025 it was $45.62M, down 2.9% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$45.62M-2.9%
FY2024Dec 31, 2024$47.00M+55.1%
FY2023Dec 31, 2023$30.29M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$18.16M+72.6%
Q2 FY2026Jun 30, 2026$22.11M+68.5%
Q1 FY2026Mar 31, 2026$20.29M+103.5%
Q4 FY2025Dec 31, 2025$12.00M+11.1%
Q3 FY2025Sep 30, 2025$10.53M-19.4%
Q2 FY2025Jun 30, 2025$13.12M-0.5%
Q1 FY2025Mar 31, 2025$9.97M+0.2%
Q4 FY2024Dec 31, 2024$10.80M+12.0%
Q3 FY2024Sep 30, 2024$13.06M+63.9%
Q2 FY2024Jun 30, 2024$13.18M+86.4%
Q1 FY2024Mar 31, 2024$9.95M+77.4%
Q4 FY2023Dec 31, 2023$9.64M–
Q3 FY2023Sep 30, 2023$7.97M–
Q2 FY2023Jun 30, 2023$7.07M–
Q1 FY2023Mar 31, 2023$5.61M–

More Alto Neuroscience figures

See a number that looks wrong?